CDK4 and breast carcinoma: In the realm of HR + /HER2- breast cancer treatment, one of the most significant advancements in recent decades is the emergence of CDK4/6i (Table 1), which have proven superior to ET alone when combined with it in the majority of patients, underscoring their pivotal role [8, 13–15].